Politics · India Bureau
ERP transformation critical for India pharma sector's manufacturing resilience
Enterprise resource planning systems are enabling Indian pharmaceutical manufacturers to modernise operations and strengthen regulatory compliance, industry leaders said. The shift away from legacy systems towards integrated digital platforms is positioning the sector for sustainable growth amid evolving global standards.
LSN India ·
Digital transformation through enterprise resource planning (ERP) is emerging as a cornerstone strategy for India's pharmaceutical industry to ensure manufacturing continuity and operational resilience, according to senior executives at the 15th Pharma IT Summit in Mumbai.
Mandar Ghatnekar, Chief Technology Officer at Biocon, highlighted how ERP modernisation replaces fragmented legacy systems with unified data architectures. "This digital evolution equips life sciences companies with the agility and data integrity required to meet stringent regulatory requirements seamlessly," Ghatnekar said at the industry gathering organised by Exito Media Concepts.
The transition addresses a critical vulnerability in pharma operations, where outdated systems pose risks to supply chain continuity and compliance documentation. Industry participants emphasised that consolidated ERP platforms create a single source of truth across manufacturing, quality assurance, and regulatory functions—essential in an industry subject to rigorous Good Manufacturing Practice (GxP) standards.
Pharmaceutical leaders attending the summit also stressed the importance of human oversight in artificial intelligence implementation within regulated environments. They underscored that successful AI adoption in pharma requires robust governance frameworks balancing technological innovation with compliance requirements and operational excellence. The consensus reflected growing recognition that digital transformation in pharmaceuticals must prioritise regulatory adherence alongside efficiency gains.